Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» M&A
M&A
Alfasigma To Acquire Intercept Pharma For $19 Per Share In Cash
Alfasigma To Acquire Intercept Pharma For $19 Per Share In Cash
RTT News
Intercept Pharma
M&A
Alfasigma
NASH
Flag link:
Enovis inks €800M deal for Italian orthopedics player Lima
Enovis inks €800M deal for Italian orthopedics player Lima
Fierce Biotech
Enovis
Medtech
M&A
Orthopedics
Lima
Flag link:
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans
BioSpace
Amgen
Horizon Therapeutics
FTC
antitrust
M&A
Flag link:
Oxford Biomedica stock soars on rosy forecast, talks to buy ABL Europe
Oxford Biomedica stock soars on rosy forecast, talks to buy ABL Europe
Reuters
Oxford BioMedica
M&A
viral vectors
ABL Europe
cell therapy
Flag link:
Boston Scientific to buy chronic back pain therapy maker Relievant
Boston Scientific to buy chronic back pain therapy maker Relievant
Reuters
M&A
Medtech
Boston Scientific
Relievant Medsystems
chronic back pain
Flag link:
Danaher’s $5.7bn acquisition of Abcam faces stand-off with founder
Danaher’s $5.7bn acquisition of Abcam faces stand-off with founder
Clinical Trials Arena
Abcam
Danaher
M&A
Flag link:
FTC, amid biopharma M&A drive, says it will take action against 'sham' patents
FTC, amid biopharma M&A drive, says it will take action against 'sham' patents
Fierce Pharma
FTC
M&A
patents
Flag link:
GE Healthcare's Independence, Acquisitions, & Bright Future
GE Healthcare's Independence, Acquisitions, & Bright Future
Medical Devices and Diagnostics Industry
Medtech
GE Healthcare
Jan Makela
M&A
Flag link:
Bausch + Lomb seeks funding for eye drug acquisition from Novartis
Bausch + Lomb seeks funding for eye drug acquisition from Novartis
BioPharma Dive
Bausch + Lomb
Novartis
M&A
Xiidra
Flag link:
Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts
Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts
Fierce Pharma
M&A
patent cliffs
Merck
JNJ
Pfizer
GSK
Novartis
Eli Lilly
Novo Nordisk
Flag link:
Kriya, flush with funding, buys a gene therapy for NASH
Kriya, flush with funding, buys a gene therapy for NASH
BioPharma Dive
Kriya Therapeutics
gene therapy
NASH
M&A
Tramontane Therapeutics
Flag link:
Abbott and Bigfoot Take Relationship to the Next Level
Abbott and Bigfoot Take Relationship to the Next Level
Medical Devices and Diagnostics Industry
Abbott Labs
Bigfoot Biomedical
M&A
Medtech
diabetes
Flag link:
Years after $2B buyout, Nestlé ditches Aimmune's peanut allergy drug Palforzia
Years after $2B buyout, Nestlé ditches Aimmune's peanut allergy drug Palforzia
Fierce Pharma
Nestle
Palforzia
peanut allergy
M&A
Stallergenes Greer
Flag link:
FTC allows Amgen’s $27.8B purchase of Horizon to proceed
FTC allows Amgen’s $27.8B purchase of Horizon to proceed
Medical Marketing and Media
FTC
Amgen
Horizon Therapeutics
M&A
Flag link:
Johnson & Johnson's spinoff of Kenvue provides $13.2B in potential M&A firepower
Johnson & Johnson's spinoff of Kenvue provides $13.2B in potential M&A firepower
Fierce Pharma
JNJ
M&A
consumer health
Kenvue
Flag link:
Novo Bolsters Obesity Pipeline with Potential $500M Embark Biotech Buy
Novo Bolsters Obesity Pipeline with Potential $500M Embark Biotech Buy
BioSpace
Novo Nordisk
Embark Biotech
obesity
M&A
Flag link:
FTC Temporarily Withdraws Challenge to $27.8B Amgen-Horizon Deal
FTC Temporarily Withdraws Challenge to $27.8B Amgen-Horizon Deal
BioSpace
FTC
Amgen
Horizon Therapeutics
M&A
Flag link:
After Catalent rumors, Danaher strikes $5.7B deal to acquire antibody specialist Abcam
After Catalent rumors, Danaher strikes $5.7B deal to acquire antibody specialist Abcam
Fierce Pharma
Danaher
Abcam
antibodies
M&A
Flag link:
'Far too speculative': Amgen fights FTC's request for injunction against $28B Horizon merger
'Far too speculative': Amgen fights FTC's request for injunction against $28B Horizon merger
Fierce Pharma
Amgen
Horizon Therapeutics
M&A
FTC
Flag link:
LEO Pharma to Acquire Timber Pharmaceuticals
LEO Pharma to Acquire Timber Pharmaceuticals
Dermatology Times
LEO Pharma
M&A
Timber Pharmaceuticals
dermatology
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »